# A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06095505/  
OnCo record `nct06095505` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Alisertib in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.

## Summary

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06095505 by Puma Biotechnology, Inc., with 120 participants planned, started 2024-02-08 and due to reach its primary completion in 2027-10-30. Interventions recorded: Alisertib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06095505
- Phase: 2
- Setting: A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Sponsor: Puma Biotechnology, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06095505: https://clinicaltrials.gov/study/NCT06095505

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Alisertib](https://onco.cc/drugs/alisertib/)
- companies: [Puma Biotechnology](https://onco.cc/companies/puma-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct06095505.json